Precision BioSciences (NASDAQ:DTIL) Trading 6.1% Higher

Precision BioSciences Inc (NASDAQ:DTIL) traded up 6.1% during mid-day trading on Friday . The company traded as high as $9.49 and last traded at $9.37, 207,879 shares were traded during mid-day trading. An increase of 16% from the average session volume of 179,524 shares. The stock had previously closed at $8.83.

A number of research analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of Precision BioSciences in a report on Tuesday, July 16th. They issued a “buy” rating and a $21.00 price objective for the company. BTIG Research initiated coverage on shares of Precision BioSciences in a report on Friday, August 9th. They set a “buy” rating and a $22.00 price target for the company. Jefferies Financial Group initiated coverage on shares of Precision BioSciences in a report on Monday, April 22nd. They set a “buy” rating for the company. Barclays initiated coverage on shares of Precision BioSciences in a report on Monday, April 22nd. They set an “overweight” rating and a $24.00 price target for the company. Finally, JPMorgan Chase & Co. initiated coverage on shares of Precision BioSciences in a report on Monday, April 22nd. They set an “overweight” rating and a $23.00 price target for the company. Six research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $22.80.

The firm has a 50-day moving average of $12.56.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.08. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $8.18 million. On average, sell-side analysts anticipate that Precision BioSciences Inc will post -1.62 EPS for the current year.

Several hedge funds have recently made changes to their positions in DTIL. FMR LLC acquired a new stake in shares of Precision BioSciences during the 1st quarter worth approximately $67,102,000. BlackRock Inc. grew its position in shares of Precision BioSciences by 511.8% during the 2nd quarter. BlackRock Inc. now owns 635,076 shares of the company’s stock worth $8,414,000 after buying an additional 531,269 shares during the period. Laurion Capital Management LP acquired a new stake in shares of Precision BioSciences during the 1st quarter worth approximately $9,295,000. Janus Henderson Group PLC acquired a new stake in shares of Precision BioSciences during the 1st quarter worth approximately $8,975,000. Finally, Wells Fargo & Company MN grew its position in shares of Precision BioSciences by 66.7% during the 2nd quarter. Wells Fargo & Company MN now owns 883,037 shares of the company’s stock worth $11,701,000 after buying an additional 353,208 shares during the period. 39.66% of the stock is owned by institutional investors.

Precision BioSciences Company Profile (NASDAQ:DTIL)

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Featured Article: Municipal Bonds

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.